Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Genocea Biosciences (GNCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 83,550
  • Shares Outstanding, K 86,580
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,710 K
  • 36-Month Beta 1.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.88

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.88 +12.52%
on 05/29/18
1.02 -2.92%
on 06/13/18
+0.01 (+1.14%)
since 05/18/18
3-Month
0.79 +25.34%
on 04/24/18
1.19 -16.79%
on 03/23/18
-0.13 (-11.59%)
since 03/20/18
52-Week
0.79 +25.34%
on 04/24/18
6.78 -85.40%
on 07/25/17
-4.34 (-81.42%)
since 06/20/17

Most Recent Stories

More News
Genocea to Present at Jefferies 2018 Global Healthcare Conference

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark, president and chief executive officer, will present a corporate...

GNCA : 0.99 (+2.61%)
Genocea Reports First Quarter 2018 Financial and Operating Results

- Company files IND for lead neoantigen vaccine program, GEN-009 -

GNCA : 0.99 (+2.61%)
Market Trends Toward New Normal in City Office REIT, Malibu Boats, Vical, Renasant, Genocea Biosciences, and Lindsay -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of City Office REIT, Inc. (NYSE:CIO),...

MBUU : 44.50 (-0.76%)
VICL : 1.26 (-3.08%)
GNCA : 0.99 (+2.61%)
CIO : 12.48 (+0.65%)
RNST : 48.10 (-0.25%)
LNN : 98.80 (+1.15%)
Genocea Files Investigational New Drug Application for Neoantigen Cancer Vaccine Candidate GEN-009

- Company plans to initiate Phase 1/2a clinical program later this year -

GNCA : 0.99 (+2.61%)
Genocea Presents Data at AACR Annual Meeting Further Highlighting Advantages of ATLAS Platform in Identification of Neoantigens over in silico Methods

- ATLAS data demonstrate in silico methods miss most empirically confirmed neoantigens -

GNCA : 0.99 (+2.61%)
Genocea to Present Data at Upcoming AACR Annual Meeting Further Highlighting ATLAS Platform Ability to Identify and Characterize Neoantigens for Cancer Vaccines

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced upcoming presentations at the 2018 Annual Meeting of the American Association...

GNCA : 0.99 (+2.61%)
Technical Perspectives on Biotech Stocks -- Eyegate Pharma, Fate Therapeutics, FibroGen, and Genocea Biosciences

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on EYEG, FATE, FGEN, and GNCA which can be accessed for free by signing up to www.wallstequities.com/registration....

GNCA : 0.99 (+2.61%)
EYEG : 0.58 (+3.57%)
FGEN : 63.90 (+3.40%)
FATE : 13.48 (+9.50%)
Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences & Manufacturing

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced the appointment of Narinder Singh as senior vice president of pharmaceutical...

GNCA : 0.99 (+2.61%)
Genocea Biosciences, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 15, 2018 / Genocea Biosciences, Inc. (NASDAQ: GNCA) will be discussing their earnings results in their Q4 Earnings Call to be held on February 15, 2018, at 9:00 AM...

GNCA : 0.99 (+2.61%)
NEA Partner Ali Behbahani, M.D. Joins Genocea Biosciences' Board of Directors

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Ali Behbahani, M.D., a partner in the healthcare group at New Enterprise...

GNCA : 0.99 (+2.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators are in flux.

See More Share

Trade GNCA with:

Business Summary

Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections,...

See More

Key Turning Points

2nd Resistance Point 1.03
1st Resistance Point 1.00
Last Price 0.99
1st Support Level 0.93
2nd Support Level 0.89

See More

52-Week High 6.78
Fibonacci 61.8% 4.49
Fibonacci 50% 3.79
Fibonacci 38.2% 3.08
Last Price 0.99
52-Week Low 0.79

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar